Evidence map›Paper›PMID 32706773›Full record

ArticlePloS one2020

Development of a brain-permeable peptide nanofiber that prevents aggregation of Alzheimer pathogenic proteins.

Naoki Tanaka, Michiaki Okuda, Tatsutoshi Nishigaki, Nobuhiko Tsuchiya, Yukako Kobayashi, Takuya Uemura, Sayaka Kumo, Hachiro Sugimoto, Seiji Miyata, Tomonori Waku

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Naoki TanakaFaculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Kyoto, Japan.
Michiaki OkudaDepartment of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.ORCID 0000-0002-0211-7144
Tatsutoshi NishigakiFaculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Kyoto, Japan.
Nobuhiko TsuchiyaFaculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Kyoto, Japan.
Yukako KobayashiFaculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Kyoto, Japan.
Takuya UemuraFaculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Kyoto, Japan.
Sayaka KumoFaculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Kyoto, Japan.
Hachiro SugimotoFaculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan.
Seiji MiyataFaculty of Applied Biology, Kyoto Institute of Technology, Kyoto, Japan.
Tomonori WakuFaculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Kyoto, Japan.ORCID 0000-0002-1342-3657
Kyoto Institute of Technology · JPDoshisha University · JPKyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is proposed to be induced by abnormal aggregation of amyloidβ in the brain. Here, we designed a brain-permeable peptide nanofiber drug from a fragment of heat shock protein to suppress aggregation of the pathogenic proteins. To facilitate delivery of the nanofiber into the brain, a protein transduction domain from Drosophila Antennapedia was incorporated into the peptide sequence. The resulting nanofiber efficiently suppressed the cytotoxicity of amyloid βby trapping amyloid β onto its hydrophobic nanofiber surface. Moreover, the intravenously or intranasally injected nanofiber was delivered into the mouse brain, and improved the cognitive function of an Alzheimer transgenic mouse model. These results demonstrate the potential therapeutic utility of nanofibers for the treatment of AD.

Indexed as

Disease Models, AnimalAdministration, IntranasalAlzheimer DiseaseAmyloid beta-PeptidesAnimalsBrainFemaleMemory DisordersMiceMice, TransgenicNanofibersPlaque, AmyloidAmyloid beta-Peptides

Identifiers

PMID32706773
PMCPMC7380640
OpenAlexW3044257489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.